Evidence map›Paper›PMID 39131954›Full record

ArticleJournal of the Society for Cardiovascular Angiography & Interventions

Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin Following WATCHMAN in High-Risk Patients.

Bryan E-Xin Tan, Mohan Rao, Bipul Baibhav, Dmitry Chuprun, Abrar Shah, Deepak L Bhatt, Jeremiah P Depta

Abstract read
In one paragraph

Article in Journal of the Society for Cardiovascular Angiography & Interventions. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bryan E-Xin TanDepartment of Internal Medicine, Rochester General Hospital, Rochester, New York.
Mohan RaoSands-Constellation Heart Institute, Rochester Regional Health, Rochester, New York.
Bipul BaibhavSands-Constellation Heart Institute, Rochester Regional Health, Rochester, New York.
Dmitry ChuprunSands-Constellation Heart Institute, Rochester Regional Health, Rochester, New York.
Abrar ShahSands-Constellation Heart Institute, Rochester Regional Health, Rochester, New York.
Deepak L BhattBrigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, Massachusetts.
Jeremiah P DeptaSands-Constellation Heart Institute, Rochester Regional Health, Rochester, New York.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In the pivotal WATCHMAN trials, warfarin was used exclusively for postprocedural anticoagulation following left atrial appendage closure. We sought to investigate the safety and efficacy of direct oral anticoagulants (DOACs) in high-risk patients with atrial fibrillation who underwent left atrial appendage closure with WATCHMAN. Methods: This was a retrospective study of 318 patients who underwent the WATCHMAN procedure in a tertiary referral center (June 2016-September 2020). We compared the outcomes of patients who were discharged on DOACs versus warfarin after the WATCHMAN procedure. The primary outcome was the composite of any bleeding, thromboembolism, or cardiovascular death through 7 ​days and 45 ​days after the procedure. Results: The final analysis included 301 patients, of whom 82.4% (248/301) were discharged on DOACs and 17.6% (53/301) were discharged on warfarin. The mean CHA Conclusions: In high-risk patients with atrial fibrillation, the primary composite outcome of any bleeding, thromboembolism, or cardiovascular death through 7 ​days and 45 ​days following WATCHMAN implantation was similar in patients receiving DOACs versus warfarin.

Indexed as

left atrial appendage occlusionnovel oral anticoagulantvitamin K antagonistwarfarinWATCHMAN

Identifiers

PMID39131954
PMCPMC11307383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.